• Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

RXi Pharmaceuticals Corp

+ Add to Watchlist


1.6000 USD 0.00000.00%

As of 20:10:00 ET on 12/26/2014.

Snapshot for RXi Pharmaceuticals Corp (RXII)

Open: 1.6000 Day's Range: 1.5900 - 1.6200 Volume: 159,161
Previous Close: 1.6000 52wk Range: 1.4000 - 6.8400 1-Yr Rtn: -43.86%

Stock Chart for RXII

No chart data available.
  • RXII:US 1.6000
  • 1D
  • 1M
  • 1Y
Interactive RXII Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RXII

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -2.0900
Est. EPS (USD) (12/2014) -0.8000
Est. PEG Ratio -
Market Cap (M USD) 33.81
Shares Outstanding (M) 21.13
30 Day Average Volume 195,842
Price/Book (mrq) 11.7563
Price/Sale (ttm) 244.6314
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/27/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RXII

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RXII

RXi Pharmaceuticals Corp. is a biotechnology company focused on discovering, developing and commercializing therapies addressing major unmet medical needs using RNAi-targeted technologies. The Company's proprietary RNA interference ("RNAi"), is a naturally occurring cellular mechanism that interferes with or silences expression of targeted disease-associated genes.

Geert CauwenberghPresident/CEO/Acting CFOPamela A PavcoChief Development Officer
More Company Profile & Key Executives for RXII

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil